[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1258734A1 - 用血栓烷-a2受體拮抗劑治療肌營養不良的組合物和方法 - Google Patents

用血栓烷-a2受體拮抗劑治療肌營養不良的組合物和方法

Info

Publication number
HK1258734A1
HK1258734A1 HK19101145.1A HK19101145A HK1258734A1 HK 1258734 A1 HK1258734 A1 HK 1258734A1 HK 19101145 A HK19101145 A HK 19101145A HK 1258734 A1 HK1258734 A1 HK 1258734A1
Authority
HK
Hong Kong
Prior art keywords
thromboxane
compositions
methods
receptor antagonists
muscular dystrophy
Prior art date
Application number
HK19101145.1A
Other languages
English (en)
Inventor
帕夫利夫·利奧
伊內絲·馬西亞斯-佩雷斯
詹姆斯·韋斯特
埃里克·卡里爾
Original Assignee
坎伯蘭醫藥品股份有限公司
范德比爾特大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 坎伯蘭醫藥品股份有限公司, 范德比爾特大學 filed Critical 坎伯蘭醫藥品股份有限公司
Publication of HK1258734A1 publication Critical patent/HK1258734A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK19101145.1A 2016-05-11 2019-01-23 用血栓烷-a2受體拮抗劑治療肌營養不良的組合物和方法 HK1258734A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662334748P 2016-05-11 2016-05-11
PCT/US2017/032151 WO2017197107A1 (en) 2016-05-11 2017-05-11 Compositions and methods of treating muscular dystrophy with thromboxane-a2 receptor antagonists

Publications (1)

Publication Number Publication Date
HK1258734A1 true HK1258734A1 (zh) 2019-11-15

Family

ID=60267383

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19101145.1A HK1258734A1 (zh) 2016-05-11 2019-01-23 用血栓烷-a2受體拮抗劑治療肌營養不良的組合物和方法

Country Status (10)

Country Link
US (4) US10064845B2 (zh)
EP (1) EP3454850B1 (zh)
JP (1) JP7003062B2 (zh)
KR (1) KR102354243B1 (zh)
CN (2) CN109152767B (zh)
AU (1) AU2017263462B2 (zh)
CA (1) CA3021356C (zh)
ES (1) ES2955158T3 (zh)
HK (1) HK1258734A1 (zh)
WO (1) WO2017197107A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3142655B1 (en) 2014-05-16 2020-12-02 Cumberland Pharmaceuticals Inc. Compositions and methods of treating cardiac fibrosis with ifetroban
EP3020403A1 (en) 2014-11-14 2016-05-18 Universitat de Valéncia Compounds for the treatment of myotonic dystrophy
AU2016285566A1 (en) 2015-06-30 2017-12-14 Cumberland Pharmaceuticals, Inc. Thromboxane receptor antagonists in AERD/asthma
WO2017197107A1 (en) * 2016-05-11 2017-11-16 Cumberland Pharmaceuticals, Inc. Compositions and methods of treating muscular dystrophy with thromboxane-a2 receptor antagonists

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2809377A1 (de) 1978-03-04 1979-09-13 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3000377A1 (de) 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US4537981A (en) 1981-11-09 1985-08-27 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane and 7-oxabicycloheptene compounds
US4416896A (en) 1982-05-17 1983-11-22 E. R. Squibb & Sons, Inc. 7-Oxabicyclopheptane substituted amino prostaglandin analogs useful in the treatment of thrombolytic disease
US4663336A (en) 1985-07-01 1987-05-05 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane substituted diamide and its congener prostaglandin analogs useful in the treatment of thrombotic disease
US4752616A (en) 1987-06-29 1988-06-21 E. R. Squibb & Sons, Inc. Arylthioalkylphenyl carboxylic acids, compositions containing same and method of use
US5066480A (en) 1988-04-11 1991-11-19 E. R. Squibb & Sons, Inc. Method of preventing or reducing adverse reactions to protamine using a thromboxane a2 receptor antagonist
US4839384A (en) 1988-10-07 1989-06-13 E. R. Squibb & Sons, Inc. Method of inhibiting onset of or treating migraine headache using a thromboxane A2 receptor antagonist
US5100889A (en) 1989-04-03 1992-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
JPH02273625A (ja) 1989-04-14 1990-11-08 Takeda Chem Ind Ltd 高エンドセリン症予防・治療剤
US4977174A (en) 1989-06-12 1990-12-11 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane imidazole prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
US5128359A (en) 1990-02-16 1992-07-07 Laboratoires Upsa Benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists, their methods of preparation
ZA911453B (en) * 1990-03-19 1991-11-27 Squibb & Sons Inc Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation
US5399725A (en) 1993-05-27 1995-03-21 Bristol-Myers Squibb Co. 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same
US5506248A (en) 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
IL110376A (en) 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical preparations containing iftroban and methods for their preparation
US6509348B1 (en) 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US20060009496A1 (en) 2004-06-15 2006-01-12 Oates John A Method for preventing hemoprotein and heme-mediated lipid peroxidation
US7358091B2 (en) 2004-12-14 2008-04-15 Portola Pharmaceuticals, Inc. Device and methods for identifying and treating aspirin non-responsive patients
JP4879977B2 (ja) 2005-06-10 2012-02-22 ドン・ア・ファーム・カンパニー・リミテッド ピラゾロピリミジノン誘導体を含む肝疾患の予防及び治療剤
WO2007075772A2 (en) * 2005-12-20 2007-07-05 President And Fellows Of Harvard College Compounds, screens, and methods of treatment
WO2008128038A2 (en) 2007-04-13 2008-10-23 The Scripps Research Institute Methods and compositions for treating cardiac dysfunctions
US20090012136A1 (en) * 2007-05-03 2009-01-08 Portola Pharmaceuticals, Inc. Unit dose formulations and methods of treating and preventing thrombosis with thromboxane receptor antagonists
US8299097B2 (en) 2008-09-12 2012-10-30 The Brigham And Women's Hospital, Inc. Methods for treating inflammatory disorders
EP2593541A4 (en) 2010-07-14 2014-01-22 Cumberland Emerging Technologies Inc METHOD FOR THE TREATMENT OF HEPATORENAL SYNDROME AND HEPATIC ENZEPHALOPATHY WITH THROMBOXANE A2 RECEPTOR ANTAGONISTS
US9785653B2 (en) * 2010-07-16 2017-10-10 Shutterfly, Inc. System and method for intelligently determining image capture times for image applications
US9624282B2 (en) * 2012-11-26 2017-04-18 The Curators Of The University Of Missouri Microdystrophin peptides and methods for treating muscular dystrophy using the same
EP3142655B1 (en) * 2014-05-16 2020-12-02 Cumberland Pharmaceuticals Inc. Compositions and methods of treating cardiac fibrosis with ifetroban
AU2016285566A1 (en) 2015-06-30 2017-12-14 Cumberland Pharmaceuticals, Inc. Thromboxane receptor antagonists in AERD/asthma
JP2019514934A (ja) 2016-04-27 2019-06-06 カンバーランド ファーマシューティカルズ，インコーポレーテッド 全身性硬化症のためのイフェトロバン治療
WO2017197107A1 (en) * 2016-05-11 2017-11-16 Cumberland Pharmaceuticals, Inc. Compositions and methods of treating muscular dystrophy with thromboxane-a2 receptor antagonists
US20180050020A1 (en) 2016-08-22 2018-02-22 Cumberland Pharmaceuticals, Inc. Ifetroban treatment of portal hypertension

Also Published As

Publication number Publication date
US10064845B2 (en) 2018-09-04
US20190142807A1 (en) 2019-05-16
EP3454850C0 (en) 2023-06-21
CA3021356A1 (en) 2017-11-16
AU2017263462B2 (en) 2021-05-13
US20180353481A1 (en) 2018-12-13
AU2017263462A1 (en) 2018-12-13
US20170340614A1 (en) 2017-11-30
CN109152767B (zh) 2022-10-21
CN109152767A (zh) 2019-01-04
JP2019515013A (ja) 2019-06-06
US10456380B2 (en) 2019-10-29
EP3454850B1 (en) 2023-06-21
ES2955158T3 (es) 2023-11-29
EP3454850A1 (en) 2019-03-20
US20200030298A1 (en) 2020-01-30
KR102354243B1 (ko) 2022-01-20
EP3454850A4 (en) 2019-11-20
KR20190021228A (ko) 2019-03-05
WO2017197107A1 (en) 2017-11-16
JP7003062B2 (ja) 2022-01-20
CN115624549A (zh) 2023-01-20
CA3021356C (en) 2023-07-25

Similar Documents

Publication Publication Date Title
IL290160A (en) Preparations and methods for the treatment of Duchenne muscular dystrophy and related disorders
IL288321A (en) Methods for treating depression using orexin-2 receptor antagonists
IL259246A (en) Preparations containing pharmaceutical substances and methods of using them
EP3207048A4 (en) Compositions and methods of treating muscular dystrophy
ZA201701909B (en) Trichoderma compositions and methods of use
HK1248531A1 (zh) 免疫調節組合物及其使用方法
HK1250710A1 (zh) 用於製備雄激素受體拮抗劑及其中間體的方法
HK1250146A1 (zh) 抗前-bcr拮抗劑和方法
HK1258734A1 (zh) 用血栓烷-a2受體拮抗劑治療肌營養不良的組合物和方法
IL251616A0 (en) Methods and compounds for the treatment and prevention of muscle loss
HK1254630A1 (zh) 肌抑素拮抗劑的用途、含有它們的組合及其用途
HK1255695A1 (zh) 用於治療眼瞼下垂的組合物和方法
IL253912B (en) Methods and compositions relating to a leptin antagonist
HK1250163A1 (zh) 作為5-氧代-ete受體拮抗劑的吲哚類似物及其使用方法
HK1257289A1 (zh) 治療和/或預防特應性皮炎的il-17c拮抗劑
IL284081A (en) Somatostatin receptor antagonistic compounds and methods of using them
PL3262069T3 (pl) Zastosowanie przeciwciał i antagonistów skierowanych przeciwko LRG1 w leczeniu